Clinical trials: Vascular Disease Risk
Infantile Hemangioma, Capillary Hemangioma
A Prospective Study on the Incidence and Related Risk Factors of Infantile Hemangioma in China
Infant hemangioma(IH) is the most common benign vascular tumor of infancy with the estimated incidence varies 1% to 12%.However, in China, the incidence of infant hemangioma and related epidemiological data remains unclear.
- Conditions
- Infantile Hemangioma, Capillary Hemangioma, Capillary Hemangiomas, Hemangioma, Capillary Infantile
- Trial name
- IH (NCT03173352)
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Risk Stratification
Predicting Ventricular Tachyarrhythmias Following Acute ST Elevation Myocardial Infarction
Predict-VT is an investigator-initiated, prospective, observational clinical trial. Four hundred patients with ST elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) will be…
- Trial name
- PREDICT-VT (NCT03263949)
- Testing
- Diagnostic
- Where
- Serbia
- Volunteers
- 400 people
- Sponsor
- Clinical Centre of Serbia
Myocardial Infarction (MI), Stroke
Smartphone Application to PREDICT Real-Time Cardiovascular Risk for Heart Attack and Stroke
To assess the diagnostic accuracy of a smartphone application in predicting heart attack or stroke within 3-4 days in high-risk patients.
- Trial name
- PREDICT-HS (NCT07735338)
- Testing
- Smartphone application Antshrike
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Stanford University
Obesity, Smoking
Africa and Middle East Cardiovascular Epidemiological Study
This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics…
- Conditions
- Obesity, Smoking, Dyslipidemia, Diabetes Mellitus
- Trial name
- ACE (NCT01243138)
- Where
- 73 sites in Algeria, Cameroon and 12 more
- Volunteers
- 4,386 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Metabolic Syndrome X, Diabetes Mellitus Type 2
Metabolic Syndrome and Related Diseases in Healthcare Workers
This study aims to investigate the incidence and prevalence of metabolic syndrome and metabolism-related diseases among healthcare workers, identify potential risk factors for these diseases, evaluate the control status of these…
- Conditions
- Metabolic Syndrome X, Diabetes Mellitus Type 2, Hypertension, Hyperlipidemia
- Trial name
- NCT06543706
- Where
- China
- Volunteers
- 7,432 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Peripheral Arterial Disease
Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life & Cardiovascular Risk in People With PAD
Peripheral arterial disease (PAD), a disabling condition, affects 800,000 Canadians. People with PAD suffer from poor quality of life due to leg pain, which makes walking difficult. They also have a high risk of heart disease.
- Trial name
- HY-PAD (NCT03649204)
- Testing
- HY-PAD
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Peripheral Arterial Disease
Exercise on Expression of Heat Shock Protein 70 in Arterial Risk
Introduction: Atherosclerotic Peripheral Arterial Disease (PAD) is the leading cause of mortality in the western world. To maintain homeostasis of the vessel wall, vascular cells produce a high level of heat shock proteins (HSP)…
- Trial name
- HSP70 (NCT04743128)
- Testing
- Exercise
- Where
- Mexico
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Universidad Popular Autónoma del Estado de Puebla
Dyslipidemia, Diabetes
Meta-analyses of Dietary Pulses and Cardiometabolic Risk
Dietary pulses, more commonly known as "legumes", are generally recognized as healthy components of the diet. Canada's Food Guide encourages consumptions of meat alternatives, such as beans "more often"; and the dietary…
- Conditions
- Dyslipidemia, Diabetes, Prediabetes, Dysglycemia
- Trial name
- NCT01594567
- Testing
- Dietary pulses
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- John Sievenpiper
Atrial Fibrillation, Atrial Fibrillation New Onset
Diagnostic Approach of Early Atrial Fibrillation, Silent Stroke and Cognitive Disorder in Patients With High-risk
The goal of this observational study is to determine the impact of the combined use of cardiac rhythm recording devices, biomarkers, echocardiogram, and Magnetic Resonance Imaging (MRI) on the early detection of AF, silent…
- Conditions
- Atrial Fibrillation, Atrial Fibrillation New Onset, Dementia, Stroke
- Trial name
- PREFA-TE (NCT05772806)
- Testing
- Electrocardiogram
- Where
- Spain
- Volunteers
- 148 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Ischaemia Reperfusion Injury
Effect of Tea on Endothelial Function and Ischaemia-reperfusion Injury
Tea consumption may impact upon the decrease in endothelial function after IR-injury. However, no previous study directly examined the potential of tea to impact upon the change in endothelial function after IR-injury.
- Trial name
- NCT01660516
- Where
- Netherlands
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Cardiovascular Risk Factor, Cardiovascular Diseases
Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction
This study is to assess LDL-C reductions at Week 52 with monthly (Q4W [≤31 days]) dosing of LIB003 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with CVD, or at high risk for CVD, on a…
- Conditions
- Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Stroke, Hypercholesterolemia
- Trial name
- LIBerate-HR (NCT04806893)
- Testing
- lerodalcibep
- Where
- 6 sites in United States, India and 1 more
- Volunteers
- 900 people
- Sponsor
- LIB Therapeutics LLC
Coronary Disease
Vitamin D Deficiency in Coronary Artery Disease
Large population cross sectional study, was conducted between 2018-2020 by attendance of 4526 patients in shiraz, Iran. Patients were undergone selective coronary angiography from radial artery approach by an expert…
- Trial name
- NCT04651101
- Testing
- coronary angiography
- Where
- Iran
- Volunteers
- 4,526 people
- Sponsor
- Shiraz University of Medical Sciences
Atherosclerotic Cardiovascular Disease
Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients
This study aims to confirm the effectiveness of ezetimibe add-on therapy on LDL-C levels compared to atorvastatin monotherapy, especially in very high-risk patients.
- Trial name
- BETTER (NCT05761444)
- Testing
- Atozet 10/40 mg or 10/80 mg, Lipitor 40 mg or 80 mg
- Where
- 7 sites in South Korea
- Volunteers
- 137 people
- Sponsor
- Organon and Co
Pre-Eclampsia, Induction of Labor
Labor Induction in Preeclampsia High-risk Women
Preeclampsia (PE) is one of the leading causes of maternal and perinatal morbidity and mortality. This pregnancy-specific disorder poses to both pregnant women and their offspring an increased risk of immediate and long-term…
- Trial name
- FORECAST-IOL (NCT05056467)
- Testing
- Induction of Labor
- Where
- 8 sites in China, Hong Kong and 5 more
- Volunteers
- 825 people
- Sponsor
- Chinese University of Hong Kong
Plasma Cell Myeloma
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
This phase II trial studies the effect of belantamab mafodotin, pomalidomide, and dexamethasone in treating patents with high-risk myeloma.
- Trial name
- NCT05208307
- Testing
- Belantamab Mafodotin, Dexamethasone, Pomalidomide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Emory University
Heart Attack, Enlarged Heart
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack.
- Trial name
- NCT05305911
- Testing
- SGLT-2 inhibitors
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Minneapolis Heart Institute Foundation
Ischemic Stroke, Acute, Dysphagia Following Cerebrovascular Accident
Dysphagia After Transesophageal Echocardiography in Acute Stroke - Follow Up Trial
The aim of the prospective observational TEDRAS - Follow-up Trial is to investigate the limitations of the initial TEDRAS - Trial in patients with acute Dysphagia is a common consequence from ischemic stroke and it correlates…
- Trial name
- TEDRAS2 (NCT06195501)
- Testing
- Flexible Endoscopic Evaluation of Swallowing (FEES) ; Transesophageal Ecocardiography (TEE)
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University of Giessen
Aortic Regurgitation, Aortic Disease
Prospective Multicenter Study Evaluating Myval TAVR Safety and Effectiveness in High-risk Severe AR
Prospective study is designed to evaluate the safety and efficacy of Myval THV series in patients with severe symptomatic non- or mild-calcified aortic regurgitation.
- Conditions
- Aortic Regurgitation, Aortic Disease, Calcified Aortic Valve
- Trial name
- MARVELTAVI (NCT07751965)
- Testing
- Myval THV series
- Volunteers
- 164 people
- Sponsor
- Ceric Sàrl
Multiple Myeloma
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
There have been four previous Total Therapy (TT1 through IIIB) studies for multiple myeloma at the MIRT from 1989 to present. Results have shown that participants treated on these studies had better outcomes (meaning they have…
- Trial name
- NCT00869232
- Testing
- Velcade, Melphalan, Thalidomide
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Arkansas
High Cardiovascular Risk, Hypertension
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
- Trial name
- KARDIA-3 (NCT06272487)
- Testing
- Zilebesiran
- Where
- 195 sites in United States, Australia and 4 more
- Volunteers
- 375 people
- Sponsor
- Alnylam Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.